6:03 AM
 | 
Mar 17, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pollinex Quattro Birch: Ph III B301 started

Allergy Therapeutics began the double-blind, placebo-controlled, European Phase III B301 trial to evaluate 900, 2,400 and 6,000 standardized units/mL subcutaneous Pollinex Quattro Birch in about...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >